Microalbumin Screening in Type 2 Diabetes and Kidney Disease
All patients with type 2 diabetes should have annual spot urine albumin-to-creatinine ratio (UACR) testing starting at diagnosis, regardless of whether they have known kidney disease. 1, 2, 3
Who Should Be Screened
Type 2 Diabetes Patients
- Screen all type 2 diabetic patients annually starting at diagnosis with spot UACR testing 1, 2, 4, 3
- This applies regardless of whether kidney disease is already known or suspected 3
- For type 1 diabetes, screening begins after 5 years of disease duration 1, 2, 4
Patients with Established Kidney Disease
- If CKD is already documented, increase monitoring frequency to 1-4 times per year depending on the stage of kidney disease 3
- More frequent testing (every 6 months) is recommended when eGFR <60 mL/min/1.73 m² or albuminuria ≥30 mg/g 5, 3
High-Risk Populations Beyond Diabetes
- Screen annually in patients with hypertension or family history of CKD, even without diabetes 5
- These populations are at increased risk and warrant the same screening approach 5
How to Screen
Preferred Method
- Use spot urine albumin-to-creatinine ratio (UACR) on a random urine sample 5, 1, 5, 6
- First-morning collections are preferred but not mandatory 5
- Timed or 24-hour collections are more burdensome and add little accuracy 1, 2, 6
Confirming Abnormal Results
- Obtain 2 of 3 positive tests within 3-6 months before diagnosing persistent albuminuria 5, 7, 8
- This accounts for the high day-to-day variability in albumin excretion (coefficient of variation ~49%) 9
- Transient elevations can occur with vigorous exercise within 24 hours, infection, fever, heart failure, marked hyperglycemia, or marked hypertension 5, 7
Interpreting Results
UACR Thresholds
- Normal: <30 mg/g creatinine 5, 2
- Moderately increased albuminuria (formerly microalbuminuria): 30-299 mg/g 5, 2, 10, 3
- Severely increased albuminuria (formerly macroalbuminuria): ≥300 mg/g 5, 2, 10, 3
Additional Testing
- Measure serum creatinine and calculate eGFR at least annually in all adults with diabetes regardless of UACR results 1, 2, 3
- Both eGFR and albuminuria are required to properly stage CKD and guide treatment decisions 6, 3
Clinical Significance
Why This Matters
- Albuminuria is the earliest clinical marker of diabetic nephropathy and predicts progression to end-stage renal disease 7, 8, 11
- Microalbuminuria increases cardiovascular mortality risk 2-4 fold in both diabetic and non-diabetic patients 7, 12
- Early detection allows intervention with ACE inhibitors or ARBs to slow progression 1, 7, 2, 3
- Increased UACR over time is associated with significantly higher healthcare costs ($15,013 vs $12,329 per person per year) 13
Real-World Testing Gaps
- While eGFR testing rates exceed 89%, UACR testing rates average only 51-53% annually across U.S. healthcare organizations 14
- This represents a major gap in guideline adherence, with testing rates varying from 13% to 75% across different practice sites 14
- Improved UACR testing would detect albuminuria in an estimated 15-30% of patients currently being missed 14
Common Pitfalls
Avoid These Errors
- Do not rely on standard urine dipstick testing for protein—it only becomes positive at >300-500 mg/day, missing microalbuminuria entirely 8, 15
- Do not measure albumin alone without creatinine—this is susceptible to false results from hydration status 1, 2, 6
- Do not diagnose persistent albuminuria on a single elevated test—confirm with 2 of 3 positive results 5, 7
- Do not assume normal UACR means no kidney disease—reduced eGFR without albuminuria occurs frequently in diabetes 6